Introduction to Cancer Biology (Part 1): Abnormal Signal Transduction
This animation is the first part of the collection “An Introduction to Cancer Cells Biology”, as well as explains the device of unusual signal transduction resulting in uncontrolled cell proliferation. This computer animation also offers an introduction of the prospective targets of anticancer therapies.
REFERRALS:
The trademarks of cancer cells. Cell.
Evaluation of epidermal growth element receptor biology. Int J Radiat Oncol Biol Phys.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Ideas to the duty of juxtacrine, paracrine as well as autocrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun; 36( 9 ):1171 -9.
4. Potapova O, Fakhrai H, Mercola D. Growth element PDGF-B/v-sis gives a tumorigenic phenotype to human tumor cells bearing PDGF receptors yet not to cells empty of receptors: evidence for an autocrine, yet not a paracrine, mechanism. Int J Cancer. 1996 May 29; 66( 5 ):669 -77.
Epidermal development element receptor mediates enhanced cell spreading, migration, as well as gathering in esophageal keratinocytes in vitro and also in vivo. J Biol Chem.
6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. When overexpressed in NIH/3T3 cells, erbb-2 is a powerful oncogene. Science. 1987 Jul 10; 237( 4811 ):178 -82.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Skin growth element ligand-independent, unregulated, cell-transforming potential of a normally occurring human mutant EGFRvIII genetics. Cell Growth Differ. 1995 Oct; 6( 10 ):1251 -9.
Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor boosts ErbB1 signaling and also generates reversible, ERK-independent loss of epithelial morphology. Int J Cancer.
Lage A, Crombet T, González G. Targeting skin development aspect receptor signaling: early results and future trends in oncology. 2003; 35( 5 ):327 -36.
10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway healthy proteins as targets for cancer cells therapy. J Clin Oncol. 2005 Aug 10; 23( 23 ):5386 -403.
Raf: a tactical target for healing advancement against cancer cells. J Clin Oncol.
TOR, a main controller of cell growth. Cell.
13. Yarden Y, Sliwkowski MX. Disentangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb; 2( 2 ):127 -37.
14. Igney FH, Krammer PH. Death as well as anti-death: tumor resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2( 4 ):277 -88.
15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An intro to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec; 1010:1 -8.
16. Veiby OP, Read MA. Chemoresistance: effect of nuclear aspect (NF)-kappaB restraint by tiny conflicting RNA. Clin Cancer Res. 2004 May 15; 10( 10 ):3333 -41.
Foo P. Metastasis: The journey of mobile cancer cells. Harvard Science Review.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial development element path in tumor growth as well as angiogenesis. J Clin Oncol. 2005 Feb 10; 23( 5 ):1011 -27.
Epidermal development element receptor in lump angiogenesis. Hematol Oncol Clin North Am.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3; 350( 23 ):2335 -42.
Task of SU11248, a multitargeted inhibitor of vascular endothelial growth aspect receptor as well as platelet-derived development aspect receptor, in people with metastatic kidney cell carcinoma. J Clin Oncol.
